# Encompass Health account plan

> Encompass Health is the largest US operator of inpatient rehabilitation hospitals, with 177 hospitals and FY2025 revenue of $5,935.2 million.

## At a glance

Encompass Health (NYSE: EHC), based in Birmingham, Alabama, owns and operates inpatient rehabilitation hospitals for patients recovering from strokes, hip fractures, neurological conditions and other major injuries or illnesses. It had 177 hospitals in 39 states and Puerto Rico at September 30, 2026, concentrated in Florida and Texas, and 92% of its patients come from acute-care hospitals. FY2025 net operating revenues were $5,935.2 million (+10.5%), net income attributable to Encompass Health $566.2 million and Adjusted EBITDA $1,267.9 million. It employs over 42,000 people (24,611 full-time), and Medicare and Medicare Advantage provided 65.4% and 16.4% of 2025 revenue. It reports a single segment, inpatient rehabilitation, and more than a third of its hospitals are joint ventures with acute-care systems.

## Business units

- **Inpatient rehabilitation** (about 97% of FY2025 net operating revenues ($5,756.3 million)): The single reportable segment: 173 hospitals and 11,465 licensed beds at end-2025 treating stroke, neurological, cardiac, pulmonary, brain and spinal cord injury and complex orthopedic patients, with 263,299 discharges in 2025. Other revenues ($178.9 million in 2025) come from supplemental Medicaid payments and management fees. Mark J. Tarr is President and CEO.

## Strategic priorities

- **Adding hospital capacity**: The pipeline beyond 2026 holds 15 hospitals with 654 beds, plus 150 to 200 bed additions in 2027; 517 beds were added in 2025 and six hospitals opened in 2026 through October.
- **Small-format hub-and-spoke hospitals**: A 24-bed small-format prototype opens from late 2027 in Conroe and Richmond, Texas; about 200 potential locations have been identified, targeting an IRR of about 20% at about $1 million per bed.
- **North Carolina expansion**: After the state repealed its certificate-of-need law effective October 1, 2026, the company prioritized 15 markets and put six real estate parcels under contract.
- **Medicare Advantage access**: An admit-and-appeal pilot overturned 87% of 294 denied claims and is being extended to every hospital and payer; VA community care volume grew 21% in Q3 2026.
- **Workforce stability**: Premium labor has fallen for 16 consecutive quarters to $23.1 million, contract labor is 0.9% of FTEs, and clinical ladders are used to retain nurses and therapists.

## Latest results

In Q3 2026 net operating revenues rose 8.9% to $1,609.5 million on 5.7% discharge growth and a 4.0% rise in net patient revenue per discharge; adjusted EBITDA grew 15.5% to $346.6 million and net income attributable to Encompass Health 18.5% to $149.9 million. Nine-month revenues were $4,793.5 million (+9.2%). Bad debt reserves rose to 2.7% of revenue from 1.9% after a billing system conversion and are expected back to 2% to 2.5% in Q4. Guidance for 2026 was raised to revenue of $6.45 billion to $6.50 billion and adjusted EBITDA of $1.395 billion to $1.415 billion.

## Investments and deals

- **2026 capital expenditure**: Capex is expected at about $920 million to $995 million in 2026 (about $736 million in 2025), with about $535 million needed to finish projects under construction.
- **Oracle Fusion ERP and billing**: The ERP moved to Oracle Fusion in October 2025 and patient billing moved from the legacy Patcom system to the Oracle module in Q2 2026.
- **Palantir partnership**: The Palantir relationship was extended and expanded after 2025 work on admission documentation and claims denials; next projects cover CRM market analysis, revenue cycle management and clinical staffing.
- **Refinancing and buybacks**: A new credit agreement in March 2026, $500 million of 5.875% Senior Notes due 2034 plus a $100 million add-on, and a buyback authorization raised to $1.0 billion, with 1.9 million shares repurchased for $203.7 million in nine months.

## Challenges and risks

- **Review choice demonstration**: From January 1, 2027, 108 of the company's hospitals (about 63% of its IRF Medicare claims) will be under prepayment review; the CFO's "greatest concern is whether or not Palmetto is going to be able to handle this administratively".
- **Medicare Advantage denials**: MA conversion rates run 25% to 30% against the mid-60% for fee-for-service Medicare, and one national payer's conversion dropped about 500 basis points in Q4 2025.
- **Billing disruption**: The Q2 2026 billing system conversion pushed bad debt to 2.7% of revenue, with legacy claims needing manual processing.
- **Reimbursement dependence**: Most revenue comes from Medicare; the 2027 Final IRF Rule raises rates about 2.3%, and the TEAM bundled-payment model is cutting lower extremity joint replacement volumes.
- **Staffing**: Shortages of nurses and therapists can force costlier contract labor; nurse turnover ticked up to 20.7% in Q3 2026.

## What leadership says

> "Our company has never before been presented with greater opportunity, and we have never been better positioned to capitalize." — Mark J. Tarr, President and Chief Executive Officer, Q4 2025 earnings call, February 6, 2026

> "we would all be collectively disappointed if we're opening less than six of those a year" — Mark J. Tarr, President and Chief Executive Officer, On small-format hospitals, Q3 2026 earnings call, October 29, 2026

> "RCD is just a new acronym for the same old thing." — Douglas E. Coltharp, Executive Vice President and Chief Financial Officer, Q4 2025 earnings call, February 6, 2026


## Where a supplier can help

- **Hospital construction and fit-out**: Tied to the capacity and small-format priorities and the 2026 capex budget: prefabricated construction, equipment and furnishing suppliers fit a pipeline of de novos, bed additions and small-format hospitals.
- **Revenue cycle and denial management**: Tied to the billing disruption, RCD and Medicare Advantage challenges: claims processing, documentation and appeals tools address the bad debt rise and prepayment review.
- **Clinical documentation AI**: Tied to the Palantir partnership and documentation burden: AI tools that reduce clinician documentation time and support medical necessity records fit the stated technology plan.
- **Nurse recruiting and retention**: Tied to the staffing challenge: recruiting, scheduling and training providers support de novo staffing teams and clinical ladder programs.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Encompass Health Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/785161/000078516126000081/ehc-20251231.htm)

Annual report · 2026-02-26

- Encompass Health is the nation's largest owner and operator of inpatient rehabilitation hospitals (IRFs) by patients treated, revenues and number of hospitals: 173 hospitals and 11,465 licensed beds in 39 states and Puerto Rico at December 31, 2025, concentrated in Florida and Texas.
- FY2025 net operating revenues were $5,935.2 million (+10.5%), driven by volume and pricing: discharges 263,299 (+6.0%, same-store +3.4%), net patient revenue per discharge $21,862 (+3.9%). Net income attributable to Encompass Health rose 24.2% to $566.2 million; segment Adjusted EBITDA was $1,267.9 million.
- Payor mix is weighted to Medicare: fee-for-service Medicare 65.4% and Medicare Advantage 16.4% of revenue; 92% of patients are admitted from acute-care hospitals.
- Growth strategy is capacity: seven new hospitals opened in 2025 plus 177 beds added to existing hospitals; de novos announced for 2026 and 2027 and 150-200 bed additions planned in each year. 2026 capex is planned at about $920 million to $995 million (2025: about $736 million).
- More than a third of hospitals are joint ventures with acute-care systems; the company owns about 79% of its hospital real estate and has no significant debt maturities until 2028.
- Workforce of over 42,000 (24,611 full-time); 2025 nurse turnover 20.2%, therapist 7.8%; contract labor FTEs fell to 355 from 427. Salaries and benefits fell to 52.5% of revenue.
- Technology: post-acute innovation strategy built on large datasets, EMR, data analytics and predictive analytics; 2025 transition to the Oracle Fusion ERP raised G&A. Oracle Health and Change Healthcare are named among third parties whose breach could disrupt operations.
- Key risks: Medicare reimbursement and audits (the 2026 IRF Rule adds about 2.9%; review choice demonstration expanding to Texas and California, covering 33 hospitals), staffing shortages, competition from acute-care hospital units, cybersecurity.
- Capital returns: 1.5 million shares repurchased for $158.0 million in 2025; quarterly dividend raised to $0.19 per share.

### [Encompass Health Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/785161/000078516126000239/ehc-20260930.htm)

Interim report · 2026-11-03

- Q3 2026 net operating revenues were $1,609.5 million (+8.9%); nine-month revenues $4,793.5 million (+9.2%), driven by volume growth and pricing.
- Q3 discharges 69,605 (+5.7%; same-store +3.0%); net patient revenue per discharge $22,543 (+4.0%); occupancy 77.0% on 11,722 licensed beds; 177 IRFs at September 30, 2026.
- Net income attributable to Encompass Health: $149.9 million in Q3 (+18.5%) and $498.3 million for nine months (+18.6%).
- Bad debt reserves rose to 2.7% of revenue from 1.9%, mainly a billing and collecting disruption after a system conversion in Q2 2026.
- Four hospitals opened in nine months (Irmo, Concordville, Loganville JV with Piedmont, Norristown) plus 85 beds; Bangor and San Antonio opened in October 2026; 2027 pipeline includes Flowood, Mississippi and a Cookeville, Tennessee JV.
- Regulation: 2027 Final IRF Rule raises Medicare rates about 2.3%; RCD will cover 108 IRFs (about 63% of IRF Medicare claims) from January 1, 2027; North Carolina repealed certificate-of-need requirements.
- Financing: new credit agreement (March 2026), $500 million of 5.875% Senior Notes due 2034 plus a $100 million add-on, $400 million of 2028 notes redeemed; about $871 million available on the revolver.
- 2026 capex expected at $920 million to $995 million; dividend raised to $0.21; buyback authorization raised to $1.0 billion, with 1.9 million shares bought for $203.7 million in nine months.

### [Encompass Health Q3 2026 earnings call (corrected transcript)](https://s203.q4cdn.com/714480614/files/doc_financials/2026/q3/CORRECTED-TRANSCRIPT_-Encompass-Health-Corp-EHC-US-Q3-2026-Earnings-Call-29-October-2026-10_00-AM-ET.pdf)

Executive talk · Douglas E. Coltharp, Executive Vice President and Chief Financial Officer · 2026-10-29

- Q3 2026: revenue +8.9%, adjusted EBITDA +15.5% to $346.6 million, adjusted EPS +23.6%; guidance raised again to revenue $6.45 billion to $6.50 billion, adjusted EBITDA $1.395 billion to $1.415 billion, adjusted EPS $6.23 to $6.37.
- Capacity is the theme: 15 announced hospitals (654 beds) beyond 2026, first small-format hospitals (Conroe and Richmond, Texas), 150 to 200 bed additions in 2027; 58 hospitals ran above 90% occupancy.
- Small-format hospitals: about 200 potential locations identified; Tarr: "we would all be collectively disappointed if we're opening less than six of those a year" by 2028-2029. Targeted IRR about 20% at about $1 million per bed.
- North Carolina repealed its Certificate of Need law on October 1: 15 markets prioritized, six real estate parcels under contract.
- Bad debt hit 2.7% after moving patient billing from the legacy Patcom system to the Oracle module; expected back to 2% to 2.5% in Q4.
- Medicare Advantage admit-and-appeal pilot: 294 claims, 87% overturned; being extended across every hospital and payer. VA volume grew 21%.
- RCD extends to 75 more hospitals (Palmetto, Jurisdiction JJ) from January 1, 2027; management doubts the MAC's administrative capacity but expects all hospitals above the 80% affirmation target.
- Labor: premium labor down for 16 consecutive quarters to $23.1 million; contract labor 0.9% of FTEs; net leverage 1.8 times.

### [Encompass Health Q4 2025 earnings call (corrected transcript)](https://s203.q4cdn.com/714480614/files/doc_financials/2025/q4/CORRECTED-TRANSCRIPT_-Encompass-Health-Corp-EHC-US-Q4-2025-Earnings-Call-6-February-2026-10_00-AM-ET.pdf)

Executive talk · Mark J. Tarr, President and Chief Executive Officer · 2026-02-06

- 2025: revenue +10.5% on 6% discharge growth; EBITDA +14.9%; premium labor spend down more than $21 million; Q4 revenue +9.9% to $1.5 billion and adjusted EBITDA +15.9% to $335.6 million.
- 2026 initial guidance: net operating revenue $6.365 billion to $6.465 billion, adjusted EBITDA $1.34 billion to $1.38 billion, adjusted EPS $5.81 to $6.10.
- 517 beds added in 2025 (390 via eight new hospitals, 127 via additions); a third modality, small-format 24-bed hospitals, starts in 2027 for a hub-and-spoke strategy.
- Technology: ERP converted to Oracle Fusion in October; the strategic relationship with Palantir was extended and expanded (admission documentation and claims denials, next CRM market analysis, revenue cycle and clinical staffing).
- Regulation: Alabama RCD affirmation about 93% (Pennsylvania 98% to 99%); Coltharp: "RCD is just a new acronym for the same old thing." TEAM covers 89 hospitals, 41 of them JVs; no volume impact seen yet.
- Medicare Advantage: conversion rates 25% to 30% vs mid-60% for fee-for-service; one national payer dropped about 500 basis points; an admit-and-appeal strategy is launched. VA is 19% of managed care volume.
- Labor: 300 net RNs added in 2025; nurse turnover 20.2%; clinical ladder participation 32% of nurses.
- Capital: 2025 adjusted free cash flow $818 million (+18.5%); net leverage 1.9 times; room for $230 million to $250 million more buybacks in 2026.

## Questions about Encompass Health

### What does Encompass Health do?

It owns and operates inpatient rehabilitation hospitals that provide intensive therapy to patients recovering from strokes, hip fractures, neurological conditions and other major injuries or illnesses, mostly referred from acute-care hospitals.

### What is Encompass Health's revenue?

FY2025 net operating revenues were $5,935.2 million (+10.5%). 2026 guidance is $6.45 billion to $6.50 billion.

### How many employees does Encompass Health have?

Over 42,000 employees, of whom 24,611 are full-time.

### Who leads Encompass Health?

Mark J. Tarr is President and CEO and Douglas E. Coltharp is Executive Vice President and CFO.

### What is Encompass Health's growth strategy?

It adds capacity through de novo hospitals, bed additions and, from 2027, small-format hospitals in a hub-and-spoke model, while expanding into North Carolina and pushing Medicare Advantage and VA volume.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
